PerMeT: Patient Perspectives on Peritoneal Metastasis Treatments
Research type
Research Study
Full title
The perspectives of palliative patients towards new treatments for peritoneal mestastases
IRAS ID
213402
Contact name
Julie Cornish
Contact email
Sponsor organisation
Cwm Taf University Health Board
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
The aim of this study is to assess patients’ attitudes and perspectives towards treatments for cancer which has spread across the lining inside the abdominal (tummy) cavity.
Current treatments include chemotherapy, administered by a drip into a vein, and surgery to remove the deposits combined with the application of heated chemotherapy solutions to the abdominal cavity during the operation. At the University Hospital of Wales in Cardiff a trial is due to begin for a new treatment called electrostatic Pressurised IntraPeritoneal Aerosol Chemotherapy (ePIPAC), which uses keyhole surgery to deliver aerosolised chemotherapy solutions to the abdominal cavity.
We will assess patients’ perceptions of these therapies, both before and after treatment. We will ask patients’ views on the information they receive about the treatments, and any effects on their quality of life, or symptoms/side-effects that they experience. Participants will be asked to take part after they have decided to have treatment. If they go ahead with the therapy and choose to participate in the study they will undertake some questionnaires and a semi-structured interview with a researcher both before and after their treatment.
We will share the results of the study with clinicians who carry out these treatments in order to improve the information provided to patients and their families in the future. This is particularly important for the new PIPAC treatment.
Any patient from Cwm Taf University Health Board Hospitals or Cardiff and Vale University Health Board Hospitals who is due to undergo one of the treatments, and who is over 18 and able to give their consent, will be eligible for inclusion. Tenovus Cancer Care has awarded a grant to fund the study.REC name
Wales REC 2
REC reference
17/WA/0247
Date of REC Opinion
14 Sep 2017
REC opinion
Favourable Opinion